Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Investing Activities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash from Investing Activities for 4 consecutive years, with $22.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 26.94% to $22.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $107.5 million through Dec 2025, up 126.4% year-over-year, with the annual reading at $107.5 million for FY2025, 126.4% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $22.4 million at Century Therapeutics, down from $24.7 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $39.2 million in Q3 2024, with the low at -$44.0 million in Q1 2022.
  • Average Cash from Investing Activities over 4 years is $12.7 million, with a median of $20.5 million recorded in 2023.
  • Peak annual rise in Cash from Investing Activities hit 829.55% in 2024, while the deepest fall reached 585.57% in 2024.
  • Over 4 years, Cash from Investing Activities stood at -$4.3 million in 2022, then soared by 535.36% to $18.6 million in 2023, then surged by 64.52% to $30.6 million in 2024, then fell by 26.94% to $22.4 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $22.4 million, $24.7 million, and $32.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.